Functional polymorphisms in the NPAS2 gene are associated with overall survival in transcatheter arterial chemoembolization‐treated hepatocellular carcinoma patients

• DOI: 10.1111/cas.12428
• Publication Date: 2014-04-23T10:20:40Z
• Authors: Peng Yuan; Shen Wang; Feng Zhou; Shaogui Wan; Yefa Yang; Xiaojun Huang; Zhaohui Zhang; Yong Zhu; Hongxin Zhang; Jinliang Xing
• Keywords: Adult; Aged, 80 and over; Male; Carcinoma, Hepatocellular; Liver Neoplasms; Nerve Tissue Proteins; Original Articles; Middle Aged; Prognosis; Polymorphism, Single Nucleotide; 3. Good health; 03 medical and health sciences; Treatment Outcome; 0302 clinical medicine; Asian People; Haplotypes; Basic Helix-Loop-Helix Transcription Factors; Humans; Chemoembolization, Therapeutic; Aged; Proportional Hazards Models

The functional abnormality of circadian regulation genes is involved in the development and progression of hepatocellular carcinoma (HCC). However, the association between functional single nucleotide polymorphisms (SNPs) in circadian gene NPAS2 and the overall survival of HCC patients treated with transcatheter arterial chemoembolization (TACE) has never been investigated. Six functional SNPs in the NPAS2 gene were genotyped using the Sequenom iPLEX genotyping system in a cohort of 448 unresectable Chinese patients with HCC treated with TACE. Multivariate Cox proportional hazards model and Kaplan–Meier curves were used for the prognosis analysis. We found that two SNPs, rs1053096 and rs2305160, in the NPAS2 gene showed significant associations with overall death risk in HCC patients in the recessive model (hazard ratio [HR] = 1.48; 95% confidence interval [CI], 1.13–1.94; P = 0.004) and in the dominant model (HR = 1.63; 95% CI, 1.29–2.07; P < 0.001), respectively. Moreover, we observed a cumulative effect of these two SNPs on HCC overall survival, indicating a significant trend of increasing death risk with increasing number of unfavorable genotypes (P for trend < 0.001). Compared with the patients without any unfavorable genotypes, the HRs for patients with one and two unfavorable genotypes were 1.41 (95% CI, 1.10–1.82; P = 0.007) and 2.09 (95% CI, 1.46–2.97, P < 0.001), respectively. The haplotype and diplotype analyses further characterized the association between NPAS2 genotype and survival of HCC patients. Our results for the first time suggest that NPAS2 gene polymorphisms may serve as an independent prognostic marker for HCC patients treated with TACE.